More trial evidence supports drug tenecteplase for acute stroke treatment
UC expert's comments at international conference featured in TCT MD
Research data presented at the European Stroke Organisation Conference last week suggests clot-busting drug tenecteplase (TNK) is an effective, if not preferred, alternative to the current standard, alteplase, to treat patients with acute ischemic stroke who require a medication to break up blood clots.
TCT MD highlighted some of the trials presented at the conference, as well as expert commentary from attendees.
Trials of alteplase, also called tPA, were pioneered at the University of Cincinnati in the late 1980s, representing the first proven treatment for ischemic stroke. TNK is a more recently developed clot-busting drug that can be administered in a single IV injection within seconds.
Some researchers at the conference said the new trial data suggests TNK should be the first choice when a medication is needed to break up a blood clot.
Commenting on a TNK trial conducted in China, Eva Mistry, MBBS, told TCT MD the encouraging results are most applicable to patients who do not have timely access to mechanical thrombectomy, a minimally invasive procedure for acute ischemic stroke patients that uses a catheter to remove a blood clot from a blood vessel in the brain, which restores blood flow.
“But I think it’s an important trial that shows us that TNK helps lyse big clots. Mechanistically, that makes sense,” said Mistry, a UC Gardner Neuroscience Institute physician researcher and assistant professor in the Department of Neurology and Rehabilitation medicine in UC’s College of Medicine.
“But I would not delay transfer for this,” Mistry continued. “I wouldn’t do anything differently other than making a case that, ‘Well, I can now give them TNK in addition to doing everything else I was to get them ready for thrombectomy.’”
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
UC Foundation celebrates 2026 philanthropy winners
October 23, 2026
The University of Cincinnati Foundation recognized its Outstanding Philanthropic Volunteer Award honorees at the George Rieveschl Recognition Dinner on October 22, 2026.
AI breast cancer survival model from Cancer Center could improve accuracy and personalize care
October 23, 2026
UC Cancer Center researchers, including lead author Wedad Alatebi, developed a deep learning survival model for breast cancer that combines detailed clinical and genetic information, potentially offering physicians a more accurate tool to guide treatment decisions.
UC expert explains potential impact of Pennsylvania’s new vape product law
October 22, 2026
UC professor Ashley Merianos speaks to the Pittsburgh Post-Gazette about Pennsylvania’s new vape law, youth vaping prevention, enforcement challenges and possible unintended consequences.